Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease

European Journal of Clinical Investigation

Volumn 37, Issue 3, 2007, Pages 180-186

  Maca, T ^a   Mlekusch, W ^a   Doweik, L ^a   Budinsky, A C ^a   Bischof, M ^a   Minar, E ^a   Schillinger, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diabetes mellitus; Lipoprotein (a); Mortality; Peripheral artery disease

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ANALYTIC METHOD; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; REGISTER; SMOKING; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 33847223475     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01747.x     Document Type: Article

References (37)

1. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
2. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol 1994;23:1091-5.
3. Vogt MT, McKenna M, Wolfson SK, Kuller LH. The relationship between ankle brachial index, other atherosclerotic disease, diabetes, smoking and mortality in older men and women. Atherosclerosis 1993;101:191-202.
4. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002;143:961-5.
5. Wilt TJ, Rubins HB, Collins D, O'Connor TZ, Rutan GH, Robins SJ. Correlates and consequence of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Arch Intern Med 1996;156:1181-8.
6. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002;22:1042-5.
7. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-8.
8. Jee SH, Suh I, Kim IS, Appel LJ. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Med Insurance Corporation Study. JAMA 1999;282:2149-55.
9. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 1994;4:40-5.
10. Tilling K, Sterne JA, Szklo M. Estimating the effect of cardiovascular risk factors on all-cause mortality and incidence of coronary heart disease using G-estimation: the atherosclerosis risk in the communities study. Am J Epidemiol 2002;155:710-8.
11. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolobon G. Lipoprotein Lp (a) and the risk for myocardial infarction. Atherosclerosis 1981;38:51-61.
12. Armstrong VW, Cremer P, Eberle E. The association between serum Lp (a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249-57.
13. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyana M. Lp (a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199-204.
14. Beckmann JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 2002;287:2570- 81.
15. Florkowski CM, Scott RS, Moir CL, Graham PJ. Lipid but not glycaemic parameters predict total mortality from type II diabetes mellitus in Canterbury, New Zealand. Diabet Med 1998;15:386-92.
16. Papademetriou V, Narayan P, Rubins H, Collins D, Robins S. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial. Am Heart J 1998;136:734- 40.
17. Cheng SW, Ting AC. Lipoprotein (a) level and mortality in patients with critical lower limb inschemia. Eur J Vasc Endovasc Surg 2001;22:124-9.
18. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000;86:897-902.
19. Assmann G, Schulte H. Identification of individuals at high risk for myocardial infarction. Atherosclerosis 1994;110:S11-21.
20. Ignatescu M, Kostner K, Zorn G, Kneussl M, Maurer G, Lang IM et al. Plasma Lp (a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost 1998;80:231-2.
21. Kostner K, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E et al. Urinary excretion of apo (a) fragments: role in apo (a) catabolism. Atheroscl Throm Vasc Biol 1996;16:905-11.
22. Kostner K, Jansen M, Maurer G, Derfler K. LDL-apheresis significantly reduces urinary apo (a) excretion. Eur J Clin Invest 1997;27:93-5.
23. Kostner K, Huber K, Stefenelli T, Rinner H, Maurer G. Urinary apo (a) discriminates coronary artery disease patients from controls. Atherosclerosis 1997;129:102-10.
24. Kostner K, Clodi M, Bodlaj G, Watschinger B, Hörl W, Derfler K et al. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 1998;28:447-52.
25. Kostner K, Banyai M, Maurer G, Hörl W, Oberbauer R. Urinary apo (a) excretion in patients with proteinuria. Ann Med 1998;30:497-502.
26. Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does lipoprotein (a) impair endothelial function? J Am Coll Cardiol 1998;31:359-65.
27. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM. The interaction of lipoprotein Lp (a) and LDL with glycosamino glycans and proteoglycans from human aorta. Arterioscler Thromb 1988;8:851-7.
28. Papagrigorakis E, Iliopoulos D, Asimacopoulos PJ, Safi HJ, Weilbaecher DJ, Ghazzaly KG et al. Lipoprotein (a) in plasma, arterial wall, and thrombus from patients with aortic aneurysms. Clin Genet 1997;52:262-71.
29. Kostner KM, Oberbauer R, Hoffmann U, Stefenelli T, Maurer G, Watschinger B. Urinary excretion of apo (a) in patients after kidney transplantation. Nephrol Dial Transplant 1997;12:2673-8.
30. Berg K, Dahlen G, Frick MH. Lp (a) lipoprotein and pre-b1-lipoprotein in patients with coronary artery disease. Clin Genet 1974;6:230-5.
31. Cushing GL, Gaubatz JW, Nava ML. Quantitation and localization of apolipoprotein (a) and B in coronary artery bypass vein grafts resected at re-operation. Atherosclerosis 1989;9:593-603.
32. Schillinger M, Domanovits H, Ignatescu M, Exner M, Bayegan K, Sedivy R et al. Lipoprotein (a) in patients with aortic aneurysms. J Vasc Surg 2002;36:25-30.
33. Schillinger M, Mlekusch W, Haumer M, Sabeti S, Maca T, Minar E. Relation of small artery compliance and lipoprotein (a) in patients with atherosclerosis. Am J Hypertens 2002;15:980-5.
34. Maca T, Ahmadi R, Derfler K, Horl WH, Koppensteiner R, Minar E et al. Elevated lipoprotein (a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis 1996;127:27-34.
35. Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators. Lp (a) lipoprotein, vascular disease, an mortality in the elderly. N Engl J Med 2003;349:2108-15.
36. Hernandez C, Francisco G, Chacon P, Simo R. Lipoprotein (a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study. Diabetes Care 2005;28:931-3.
37. Vanzetto G, Halimi S, Hammoud T, Fagret D, Benhamou PY, Cordonnier D et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care 1999;22:19-26.